PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24700885-3 2014 Our aim was to determine whether treatment with the antianginal agent trimetazidine, which inhibits fatty acid oxidation in the heart secondary to inhibition of 3-ketoacyl-CoA thiolase (3-KAT), may have off-target effects on glycemic control in obesity. Trimetazidine 70-83 thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 Mus musculus 188-191 25064584-4 2014 A 3-week treatment with the 3-KAT inhibitor trimetazidine prevented obesity-induced reduction in both systolic and diastolic function. Trimetazidine 44-57 thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 Mus musculus 30-33 24700885-4 2014 We fed C57BL/6NCrl mice a high-fat diet (HFD) for 10 weeks before a 22-day treatment with the 3-KAT inhibitor trimetazidine (15 mg/kg per day). Trimetazidine 110-123 thiosulfate sulfurtransferase (rhodanese)-like domain containing 1 Mus musculus 96-99